Phosphorylation-Dependent Regulation and Interactions of the Neutral Amino Acid Transporter SLC6A15: Implications for Major Depression and Neuropsychiatric Disorders
Restricted accessResearch articleFirst published online February, 2026
Phosphorylation-Dependent Regulation and Interactions of the Neutral Amino Acid Transporter SLC6A15: Implications for Major Depression and Neuropsychiatric Disorders
SLC6A15, (sodium-dependent neutral amino acid transporter B(0)AT2), plays a crucial role in amino acid homeostasis and neuronal signaling, and it has been genetically and transcriptionally associated with major depressive disorder (MDD). However, the post-translational regulation of SLC6A15, particularly through phosphorylation, remains poorly understood. To address this knowledge gap, we report here curation of 3825 global phosphoproteomic datasets and layered statistical and bioinformatic analyses to uncover predominant phosphosites, co-phospho-regulated proteins, upstream kinases, and binary interactors of SLC6A15. Importantly, after stringent filtration, three sites, pS701, pS699, and pS687, were identified as the predominant sites of phosphorylation. Predicted upstream kinases included mitogen-activated protein kinase 3 (MAPK3) and cyclin-dependent kinase 12 (CDK12), suggesting regulatory control at these phosphorylation sites. Binary interactors such as tyrosine-protein kinase Lyn, epidermal growth factor receptor, and calnexin were found to have direct associations with stress-related pathways, indicating potential roles in stress-responsive signaling mechanisms. Pathway enrichment analysis of the high-confidence phosphosites in other proteins revealed significant enrichment of the ErbB signaling pathway, which is frequently dysregulated in MDD. Collectively, this study presents a comprehensive co-phospho-regulation-based catalog of SLC6A15, systematically mapping its key phosphorylation sites, regulatory kinases, and interaction partners. Identification of upstream kinases such as MAPK3 and CDK12 and enrichment of the ErbB signaling axis indicate a potential role of SLC6A15 in synaptic plasticity, neuronal signaling, and stress response mechanisms associated with depression. These findings uncover novel protein–protein relationships and phosphorylation-driven interactions, offering new insights into transporter regulation in neuropsychiatric disorders and potential therapeutic targets for MDD.
Abu-AtaS, ShukhaON, Awad-IgbariaY, et al.Blocking the ErbB pathway during adolescence affects the induction of anxiety-like behavior in young adult maternal immune activation offspring. Pharmacol Biochem Behav, 2023; 222:173497; doi: 10.1016/j.pbb.2022.173497
2.
ArditoF, GiulianiM, PerroneD, et al.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (review). Int J Mol Med, 2017; 40(2):271–280; doi: 10.3892/ijmm.2017.3036
BellilH, GhiehF, HermelE, et al.Human Testis-Expressed (TEX) Genes: A review focused on spermatogenesis and male fertility. Basic Clin Androl, 2021; 31(1):9; doi: 10.1186/s12610-021-00127-7
5.
BlazekD, KohoutekJ, BartholomeeusenK, et al.The Cyclin K/Cdk12 Complex Maintains Genomic Stability via Regulation of Expression of DNA Damage Response Genes. Genes Dev, 2011; 25(20):2158–2172; doi: 10.1101/gad.16962311
6.
ChenY, LiH, LiangW, et al.SLC6A15 Acts as a Tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer. J Cell Biochem, 2021; 122(8):814–826; doi: 10.1002/jcb.29914
7.
CitriA, YardenY. EGF-ERBB Signalling: Towards the systems level. Nat Rev Mol Cell Biol, 2006; 7(7):505–516; doi: 10.1038/nrm1962
8.
ConnerSD, SchmidSL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Biol, 2002; 156(5):921–929; doi: 10.1083/jcb.200108123
9.
Costa-MattioliM, MonteggiaLM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci, 2013; 16(11):1537–1543; doi: 10.1038/nn.3546
10.
DangR, CaiH, ZhangL, et al.Dysregulation of neuregulin-1/erbb signaling in the prefrontal cortex and hippocampus of rats exposed to chronic unpredictable mild stress. Physiol Behav, 2016; 154:145–150; doi: 10.1016/j.physbeh.2015.11.023
11.
de BartolomeisA, VellucciL, De SimoneG, et al.Dysregulated signaling at postsynaptic density: A systematic review and translational appraisal for the pathophysiology, clinics, and antipsychotics’ treatment of schizophrenia. Cells, 2023; 12(4):574; doi: 10.3390/cells12040574
12.
DinkelH, ChicaC, ViaA, et al.Phospho.ELM: A Database of phosphorylation sites–Update 2011. Nucleic Acids Res, 2011; 39(Database issue):D261–D7; doi: 10.1093/nar/gkq1104
13.
DrgonovaJ, JacobssonJA, HanJC, et al.Involvement of the neutral amino acid transporter SLC6A15 and leucine in obesity-related phenotypes. PLoS One, 2013; 8(9):e68245; doi: 10.1371/journal.pone.0068245
14.
EastMP, AsquithCRM. CDC42BPA/MRCKα: A Kinase target for brain, ovarian and skin cancers. Nat Rev Drug Discov, 2021; 20(3):167; doi: 10.1038/d41573-021-00023-9
15.
GeSX, JungD, YaoR. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics, 2020; 36(8):2628–2629; doi: 10.1093/bioinformatics/btz931
16.
HägglundMGA, RoshanbinS, LöfqvistE, et al.B(0)AT2 (SLC6A15) is localized to neurons and astrocytes and is involved in mediating the effect of leucine in the brain. PLoS One, 2013; 8(3):e58651; doi: 10.1371/journal.pone.0058651
17.
HornbeckPV, ZhangB, MurrayB, et al.PhosphoSitePlus, 2014: Mutations, PTMs and Recalibrations. Nucleic Acids Res, 2015; 43(Database issue):D512–D20; doi: 10.1093/nar/gku1267
18.
HuangK-Y, WuH-Y, ChenY-J, et al.RegPhos 2.0: An updated resource to explore protein kinase-substrate phosphorylation networks in mammals. Database (Oxford), 2014; 2014(0):bau034; doi: 10.1093/database/bau034
19.
IngleyE. Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta, 2008; 1784(1):56–65; doi: 10.1016/j.bbapap.2007.08.012
20.
Keshava PrasadTS, GoelR, KandasamyK, et al.Human protein reference database–2009 Update. Nucleic Acids Res, 2009; 37(Database issue):D767–D72; doi: 10.1093/nar/gkn892
21.
KristensenAS, AndersenJ, JørgensenTN, et al.SLC6 neurotransmitter transporters: Structure, function, and regulation. Pharmacol Rev, 2011; 63(3):585–640; doi: 10.1124/pr.108.000869
22.
KukułowiczJ, Pietrzak-LichwaK, KlimończykK, et al.The SLC6A15-SLC6A20 neutral amino acid transporter subfamily: Functions, diseases, and their therapeutic relevance. Pharmacol Rev, 2023; 76(1):142–193; doi: 10.1124/pharmrev.123.000886
23.
LedonneA, MercuriNB. mGluR1-dependent long term depression in rodent midbrain dopamine neurons is regulated by neuregulin 1/ErbB Signaling. Front Mol Neurosci, 2018; 11:346; doi: 10.3389/fnmol.2018.00346
24.
LiaoD, GuoY, XiangD, et al.Dysregulation of neuregulin-1/ErbB signaling in the hippocampus of rats after administration of doxorubicin. Drug Des Devel Ther, 2018; 12:231–239; doi: 10.2147/DDDT.S151511
25.
LiX, YuanR-R, WangQ, et al.Brain-Derived neurotrophic factor regulates LYN Kinase-Mediated myosin light chain kinase activation to modulate nonmuscle myosin II activity in hippocampal neurons. J Biol Chem, 2022; 298(6):102054; doi: 10.1016/j.jbc.2022.102054
26.
LundegaardPR, AnastasakiC, GrantNJ, et al.MEK inhibitors reverse cAMP-Mediated anxiety in zebrafish. Chem Biol, 2015; 22(10):1335–1346; doi: 10.1016/j.chembiol.2015.08.010
27.
MahinA, GopalakrishnanAP, AhmedM, et al.Orchestrating intracellular calcium signaling cascades by phosphosite-centric regulatory network: A comprehensive analysis on kinases CAMKK1 and CAMKK2. OMICS, 2025; 29(4):139–153; doi: 10.1089/omi.2024.0196
28.
MalsamJ, SatohA, PelletierL, et al.Golgin tethers define subpopulations of COPI Vesicles. Science, 2005; 307(5712):1095–1098; doi: 10.1126/science.1108061
29.
MaT, HoefferCA, Capetillo-ZarateE, et al.Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of alzheimer’s disease. PLoS One, 2010; 5(9):e12845; doi: 10.1371/journal.pone.0012845
30.
McFarlandDC, JutagirDR, RosenfeldB, et al.Depression and inflammation among epidermal growth factor receptor (EGFR) Mutant Nonsmall cell lung cancer patients. Psychooncology, 2019; 28(7):1461–1469; doi: 10.1002/pon.5097
31.
McNallyKE, FaulknerR, SteinbergF, et al.Retriever is a multiprotein complex for retromer-independent endosomal cargo recycling. Nat Cell Biol, 2017; 19(10):1214–1225; doi: 10.1038/ncb3610
32.
MeiL, NaveK-A. Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases. Neuron, 2014; 83(1):27–49; doi: 10.1016/j.neuron.2014.06.007
33.
MitraS, WernerC, DietzDM. Neuroadaptations and TGF-β signaling: Emerging role in models of neuropsychiatric disorders. Mol Psychiatry, 2022; 27(1):296–306; doi: 10.1038/s41380-021-01186-y
34.
MostaidMS, LeeTT, ChanaG, et al.Peripheral transcription of pathway genes are upregulated in treatment-resistant schizophrenia. Front Psychiatry, 2017; 8:225; doi: 10.3389/fpsyt.2017.00225
35.
MuFT, CallaghanJM, Steele-MortimerO, et al.EEA1, an early endosome-associated protein. EEA1 Is a conserved alpha-helical peripheral membrane protein flanked by cysteine “fingers” and contains a calmodulin-binding IQ Motif. J Biol Chem, 1995; 270(22):13503–13511; doi: 10.1074/jbc.270.22.13503
36.
NguyenYTK, HaHTT, NguyenTH, et al.The role of slc transporters for brain health and disease. Cell Mol Life Sci, 2021; 79(1):20; doi: 10.1007/s00018-021-04074-4
37.
OltuluF, KocatürkDÇ, AdalıY, et al.Autophagy and mTOR pathways in mouse embryonic stem cell, lung cancer and somatic fibroblast cell lines. J Cell Biochem, 2019; 120(10):18066–18076; doi: 10.1002/jcb.29110
38.
OughtredR, RustJ, ChangC, et al.The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci, 2021; 30(1):187–200; doi: 10.1002/pro.3978
39.
ParcaL, ArianoB, CabibboA, et al.Kinome-Wide identification of phosphorylation networks in eukaryotic proteomes. Bioinformatics, 2019; 35(3):372–379; doi: 10.1093/bioinformatics/bty545
40.
PriyankaP, GopalakrishnanAP, NisarM, et al.A global phosphosite-correlated network map of thousand and one kinase 1 (TAOK1). Int J Biochem Cell Biol, 2024; 170:106558; doi: 10.1016/j.biocel.2024.106558
41.
QuastC, CuboniS, BaderD, et al.Functional coding variants in SLC6A15, a possible risk gene for major depression. PLoS One, 2013; 8(7):e68645; doi: 10.1371/journal.pone.0068645
42.
RameshST, NavyasreeKV, SahS, et al.BMP2K phosphorylates AP-2 and regulates Clathrin-mediated endocytosis. Traffic, 2021; 22(11):377–396; doi: 10.1111/tra.12814
43.
RautSB, JolyF, HaassNK, et al.The clinically relevant MEK Inhibitor Mirdametinib Combined with D-Cycloserine and Prediction Error Disrupts Fear Memory in PTSD Models. Transl Psychiatry, 2024; 14(1):492; doi: 10.1038/s41398-024-03190-6
44.
SanjeevD, GeorgeM, JohnL, et al.Tyr352 as a Predominant phosphosite in the understudied kinase and molecular Target, HIPK1: Implications for cancer therapy. OMICS, 2024; 28(3):111–124; doi: 10.1089/omi.2023.0244
45.
SantarelliS, NamendorfC, AnderzhanovaE, et al.The amino acid transporter SLC6A15 Is a regulator of hippocampal neurochemistry and behavior. J Psychiatr Res, 2015; 68:261–269; doi: 10.1016/j.jpsychires.2015.07.012
46.
SantarelliS, WagnerKV, LabermaierC, et al.SLC6A15, a novel stress vulnerability candidate, modulates anxiety and depressive-like behavior: Involvement of the glutamatergic system. Stress, 2016; 19(1):83–90; doi: 10.3109/10253890.2015.1105211
47.
SawickaK, ZukinRS. Dysregulation of mTOR signaling in neuropsychiatric disorders: Therapeutic implications. Neuropsychopharmacology, 2012; 37(1):305–306; doi: 10.1038/npp.2011.210
48.
SealRL, BraschiB, GrayK, et al.Genenames.org: The HGNC resources in 2023. Nucleic Acids Res, 2023; 51(D1):D1003–D1009; doi: 10.1093/nar/gkac888
49.
SkibinskaM, KapelskiP, Dmitrzak-WeglarzM, et al.Elevated epidermal growth factor (EGF) as candidate biomarker of mood disorders-longitudinal study in adolescent and young adult Patients. J Clin Med, 2021; 10(18):4064; doi: 10.3390/jcm10184064
50.
TakanagaH, MackenzieB, PengJ-B, et al.Characterization of a branched-chain amino-acid transporter SBAT1 (SLC6A15) that is expressed in human brain. Biochem Biophys Res Commun, 2005; 337(3):892–900; doi: 10.1016/j.bbrc.2005.09.128
51.
TakedaK, IchijoH. Neuronal p38 MAPK Signalling: An emerging regulator of cell fate and function in the nervous system. Genes Cells, 2002; 7(11):1099–1111; doi: 10.1046/j.1365-2443.2002.00591.x
52.
TatuU, HeleniusA. Interactions between newly synthesized glycoproteins, calnexin and a network of resident chaperones in the endoplasmic reticulum. J Cell Biol, 1997; 136(3):555–565; doi: 10.1083/jcb.136.3.555
TomasA, FutterCE, EdenER. EGF receptor trafficking: Consequences for signaling and cancer. Trends Cell Biol, 2014; 24(1):26–34; doi: 10.1016/j.tcb.2013.11.002
55.
TsitsiridisG, SteinkampR, GiurgiuM, et al.CORUM: The comprehensive resource of mammalian protein complexes-2022. Nucleic Acids Res, 2023; 51(D1):D539–D545; doi: 10.1093/nar/gkac1015
56.
UniProt Consortium. UniProt: The universal protein knowledgebase in 2023. Nucleic Acids Res, 2023; 51(D1):D523–D531; doi: 10.1093/nar/gkac1052
57.
WangW, QiaoY, QuH, et al.The protective role of neuregulin1-ErbB4 signaling in a chronic social defeat stress model. Neuroreport, 2020; 31(9):678–685; doi: 10.1097/WNR.0000000000001464
58.
YoshidaK, KandaS, ShiraishiH, et al.Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with -mutated non-small cell lung cancer: A retrospective study. J Thorac Dis, 2019; 11(4):1347–1354; doi: 10.21037/jtd.2019.03.61
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
